Patients to PBMs: Give us choices, not mandatory mail!
It’s no secret that managed care has steered millions of Americans into ordering their maintenance medications by mail. But pharmacy benefit managers should take note: Most patients don’t like the arrangement.
That much was clear from the results of an exclusive survey of nearly 800 patients conducted by AccentHealth and Drug Store News in late July and early August. Of the 90% of those patients who expressed a preference for a particular pharmacy channel as their chief source for prescription medicines, only 2% named a mail-order provider as their preferred pharmacy. You read that right: When given a choice, just 1-out-of-every-50 patients would rather get their scripts by mail.
That means the vast majority of survey respondents with a preference for one pharmacy over another said they’d rather have their prescriptions filled personally by their local retail pharmacist. Chain drug stores were the clear favorite, with 53% expressing a preference for that type of pharmacy outlet, but mass merchants, supermarkets, independent pharmacies and club stores also easily outranked the mail-order option.
The poll was conducted for Patient Views, a new, exclusive consumer insights feature that will be appear in every edition of DSN magazine and the daily e-newsletter DSN A.M.
DSN editor-in-chief Rob Eder called the findings "a strong indication that pharmacy retailers need to pump more investment into pharmacy customer engagement and efforts to transform the drug store from just a dispensary of prescriptions to a destination for a broader array of health services."
If you’re a practicing pharmacist, you’ve probably encountered patients who expressed their views, pro or con, about the mail option. You can share those views by clicking on the link below. As always, I’d welcome your input.
FDA approves smaller-dose Afinitor for rare brain tumor in children
SILVER SPRING, Md. — The Food and Drug Administration has approved a new formulation of a cancer drug made by Novartis for a type of brain tumor in children, the agency said.
The FDA announced the approval of Afinitor Disperz (everolimus) tablets for oral suspension to treat a rare brain tumor called subependymal giant-cell astrocytoma, or SEGA. The agency said Afinitor Disperz, a new dosage form of the drug Afinitor, is the first pediatric-specific dosage form for a pediatric tumor to receive FDA approval.
The drug, designed to dissolve in water, is recommended for patients aged 1 year and older with tuberous sclerosis complex who are diagnosed with SEGA that can’t be treated with surgery. TSC is a rare genetic disease that causes tumors to grow in the brain and other vital organs, while SEGA is a slow-growing tumor that can cause life-threatening complications by blocking the flow of blood to the brain, occurring in 6-9% of TSC patients.
Astellas, Medivation cancer drug wins FDA approval
SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug made by Astellas Pharma U.S. and Medivation for treating prostate cancer, the agency said Friday.
The FDA announced the approval of Xtandi (enzalutamide) for castration-resistant prostate cancer that has spread or recurred despite medical or surgical therapy to minimize testosterone.
"The need for additional treatment options for advanced prostate cancer continues to be important for patients," FDA Office of Hematology and Oncology Products director Richard Pazdur said. "Xtandi is the latest treatment for this disease to demonstrate its ability to extend a person’s life."
About 241,740 men will be diagnosed with prostate cancer, and 28,170 will die from it this year, according to the National Cancer Institute, part of the National Institutes of Health.